---
title: "Liquidia Corp 2026: Revenue $171.68M, EPS $0.74— 10-Q Summary"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/295652655.md"
description: "Liquidia Corp reported Q2 2026 revenue of $171.68M and diluted EPS of $0.74, a significant increase from the prior year's $8.84M revenue and -$0.49 EPS. This growth is attributed to the commercial launch of YUTREPIA in June 2025. The company continues its profit-share promotion with Sandoz for Treprostinil Injection, though pump availability limits uptake. R&D spending increased to advance L606 programs and new indications for YUTREPIA. Manufacturing agreements with Lonza and LGM ensure commercial supply."
datetime: "2026-08-12T10:51:02.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/295652655.md)
  - [en](https://longbridge.com/en/news/295652655.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/295652655.md)
generator: "portal-rs"
---

# Liquidia Corp 2026: Revenue $171.68M, EPS $0.74— 10-Q Summary

Liquidia Corp reported results for the quarter ended 2026 with revenue of $171.68M and diluted EPS of $0.74, versus $8.84M revenue and ($0.49) EPS in the prior-year quarter, reflecting a material commercial ramp following the June 2025 launch of YUTREPIA.

**Financial Highlights**

Metric

Current quarter

Prior year quarter

YoY change

Revenue¹

$171.68M

$8.84M

1842.7%

Net income²

$74.72M

($41.58M)

279.7%

Diluted EPS³

$0.74

($0.49)

251%

*¹ Reported as “Total revenue”. ² Reported as “Net income (loss) and comprehensive income (loss)”. ³ Reported as “Net income (loss) per common share, diluted”.*

**Business Highlights**

-   YUTREPIA commercial launch (June 2025) drove the large sequential and year-over-year revenue increase, supported by targeted field force and patient support programs.
-   Continued profit-share promotion with Sandoz for Treprostinil Injection; pump availability is limiting subcutaneous patient uptake.
-   R&D spending increased to advance L606 programs and potential additional indications for YUTREPIA, including PH-COPD, IPF, PPF and SSc-RP.
-   Manufacturing and supply agreements with Lonza and LGM are in place, and non-cancelable manufacturing commitments support commercial supply.

Original SEC Filing: Liquidia Corp \[ LQDA \] - 10-Q - Aug. 12, 2026

**Disclaimer**

This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.

### Related Stocks

- [LQDA.US](https://longbridge.com/en/quote/LQDA.US.md)
- [LGM.US](https://longbridge.com/en/quote/LGM.US.md)
- [SDZNY.US](https://longbridge.com/en/quote/SDZNY.US.md)

## Related News & Research

- [Liquidia (LQDA) Turns Profitable On YUTREPIA Growth, Is The Upside Already Priced In?](https://longbridge.com/en/news/296513877.md)
- [Rajeev Saggar Sells 50,000 Shares of Liquidia (NASDAQ:LQDA) Stock](https://longbridge.com/en/news/296477852.md)
- [Liquidia director Katherine Rielly-Gauvin reports common share sale worth $4.08 million](https://longbridge.com/en/news/296650554.md)
- [Liquidia Chief Medical Officer Rajeev Saggar disposes of USD 5.97 million in common shares](https://longbridge.com/en/news/296406687.md)
- [Renaissance Technologies LLC Sells 198,753 Shares of Liquidia Corporation $LQDA](https://longbridge.com/en/news/296325354.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**